BOSTON, Sept. 27, 2021 /PRNewswire/ — Preclinical neuroscience company Delix Therapeutics (the “Company”), today announced the closing of a $70 million Series A financing round. The round was led by ARTIS Ventures, RA Capital Management, and founding investor OMX Ventures, with participation from a diverse syndicate of life sciences and psychedelic investment funds. The Company expects to use the…


Previous articleToronto University Health Network Launches Psychedelic Psychotherapy Research Centre
Next articleBetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders